BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02Unregistered Sales of Equity Securities.
On April 17, 2017, May 5, 2017, June 20, 2017 and June 30, 2017 BioSig Technologies, Inc. (the “Company”) consummated a second, third, fourth and fifth closing, respectively under the Unit Purchase Agreement, dated April 6, 2017, by and among the Company and certain accredited investors (the “Purchase Agreement”), to which the Company issued to certain accredited investors (the “April-June Investors”) an aggregate of 399,933 units (the “Units”), in exchange for aggregate consideration of $599,898. Each Unit consists of one share (the “Investor Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and a warrant to purchase one half of one share of Common Stock, exercisable at a price of $1.50 per share (the “Investor Warrants”), at a per Unit price of $1.50. In addition, in connection with the second, third, fourth and fifth closings, each April-June Investor became party to that certain Registration Rights Agreement, dated as of April 6, 2017.
As previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2017 the Company consummated the first closing under the Purchase Agreement on April 6, 2017, to which the Company issued to the initial investors (the “Initial Investors” and collectively with the April-June Investors, the “Investors”) an aggregate of 426,667 Units in exchange for aggregate consideration of $640,000.
The Units, Investor Shares and Investor Warrants issued and sold to the Investors were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act, provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act. Each Investor represented that it was an accredited investor (as defined by Rule 501 under the Securities Act).
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
